Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, Research Support, N.I.H., Intramural, práce podpořená grantem
Grantová podpora
UM1 HG006504
NHGRI NIH HHS - United States
75N91019D00024
NCI NIH HHS - United States
R01 AI091707
NIAID NIH HHS - United States
S10 OD018521
NIH HHS - United States
2U19 AI111825
NIH HHS - United States
ZIA AI001270
Intramural NIH HHS - United States
MR/S032304/1
Medical Research Council - United Kingdom
U19 AI111825
NIAID NIH HHS - United States
R01 AI163029
NIAID NIH HHS - United States
P01 AI138398-S1
NIH HHS - United States
1ZIA AI001265
Intramural NIH HHS - United States
Howard Hughes Medical Institute - United States
UL1 TR001866
NCATS NIH HHS - United States
R01 AI088364
NIAID NIH HHS - United States
R01 AI091707-10S1
NIH HHS - United States
ZIA AI001265
Intramural NIH HHS - United States
U24 HG008956
NHGRI NIH HHS - United States
PubMed
34413139
PubMed Central
PMC8521484
DOI
10.1126/sciimmunol.abl4340
PII: 6/62/eabl4340
Knihovny.cz E-zdroje
- MeSH
- autoprotilátky krev imunologie MeSH
- COVID-19 imunologie mortalita MeSH
- dítě MeSH
- dospělí MeSH
- imunoglobulin G krev imunologie MeSH
- interferon alfa imunologie MeSH
- interferon typ I imunologie MeSH
- kojenec MeSH
- kritický stav MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- neutralizující protilátky krev imunologie MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- studie případů a kontrol MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- kojenec MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
- Research Support, N.I.H., Intramural MeSH
- Názvy látek
- autoprotilátky MeSH
- imunoglobulin G MeSH
- interferon alfa MeSH
- interferon omega 1 MeSH Prohlížeč
- interferon typ I MeSH
- neutralizující protilátky MeSH
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100 pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-β. We also show, in a sample of 34,159 uninfected subjects from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals <70 years, 2.3% between 70 and 80 years, and 6.3% >80 years. By contrast, auto-Abs neutralizing IFN-β do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases.
Aix Marseille Université IRD APHM MEPHI Marseille France
AP HP Bichat Claude Bernard Hospital Infectious and Tropical Diseases Department Paris France
AP HP Département Epidémiologie Biostatistiques et Recherche Clinique Hôpital Bichat Paris France
Cancer Genetics and Prevention Program University of California San Francisco San Francisco USA
Catalan Institution for Research and Advanced Studies Barcelona Spain
Cerba Health Care Issy les Moulineaux France
Chair of Human Genomics and Evolution Collège de France Paris France
CHU Lille Pôle de Réanimation Hôpital Roger Salengro Lille France
CIBER de Enfermedades Respiratorias Instituto de Salud Carlos 3 Madrid Spain
College of Medicine Imam Abdulrahman Bin Faisal University Dammam Saudi Arabia
CREA Laboratory Diagnostic Department ASST Spedali Civili di Brescia Brescia Italy
Department of Biomedicine Aarhus University Aarhus Denmark
Department of Biosciences and Nutrition Karolinska Institutet Stockholm Sweden
Department of Clinical Immunology Rigshospitalet Copenhagen University Hospital Copenhagen Denmark
Department of Clinical Laboratory Hospital Universitari de Bellvitge IDIBELL Barcelona Spain
Department of Critical Care Medicine Clinica Universidad de La Sabana Chia Colombia
Department of Genetics Yale University School of Medicine New Haven CT USA
Department of Hematology Necker Hospital AP HP Paris France
Department of Immunology Hospital Universitari de Bellvitge IDIBELL Barcelona Spain
Department of Immunology Institute of Biomedical Sciences University of Sao Paulo Sao Paulo Brazil
Department of Infectious Diseases Aarhus University Hospital Skejby Denmark
Department of Infectious Diseases San Gerardo Hospital University of Milano Bicocca Monza Italy
Department of Internal Medicine 2 Medical University of Innsbruck Innsbruck Austria
Department of Internal Medicine Hospital Universitari de Bellvitge IDIBELL Barcelona Spain
Department of Internal Medicine Infanta Leonor University Hospital Madrid Spain
Department of Medical Genetics Acibadem University School of Medicine Istanbul Turkey
Department of Medical Gerontology School of Medicine Trinity College Dublin
Department of Medical Microbiology University Medical Center Utrecht Utrecht Netherlands
Department of Microbiology Universidad de La Sabana Chia Colombia
Department of Molecular Biology and Genetics Bilkent University Bilkent Ankara Turkey
Department of Neurology Amsterdam Neuroscience Amsterdam Netherlands
Department of Neurosurgery Yale University School of Medicine New Haven CT USA
Department of Paediatrics and Adolescent Medicine The University of Hong Kong Hong Kong China
Department of Pediatrics Fondazione IRCCS Policlinico San Matteo University of Pavia Pavia Italy
Department of Pediatrics King Fahad Hospital of the University Al Khobar Saudi Arabia
Diabetes Center University of California San Francisco CA USA
Diabetes Research Institute IRCCS San Raffaele Scientific Institute Milan Italy
Division of Geriatric Medicine Tours University Medical Center Tours France
Etablissement Français du Sang Auvergne Rhône Alpes St Etienne St Etienne France
Etablissement Français du Sang La Plaine St Denis France
Faculdades Pequeno Príncipe Instituto de Pesquisa Pelé Pequeno Príncipe Curitiba Brazil
Faculty of Medical Sciences University Goce Delchev Stip Republic of Northern Macedonia
Feinstein Institutes for Medical Research Northwell Health Manhasset NY USA
Fundación Rioja Salud Centro de Investigación Biomédica de La Rioja Logrono Spain
Garvan Institute of Medical Research Sydney Australia
Hematology and Bone Marrow Transplantation Unit IRCCS San Raffaele Scientific Institute Milano Italy
Hospital Universitari Mutua Tarrassa Tarrasa Spain
Hospital Universitario de Gran Canaria Dr Negrín Canarian Health System Canary Islands Spain
Howard Hughes Medical Institute New York NY USA
Human Evolutionary Genetics Unit Institut Pasteur CNRS UMR 2000 Paris France
Imagine Institute Université de Paris INSERM UMR 1163 Paris France
Infectious Diseases and Immunity Center for Health and Social Care Research Vic Spain
INSERM U1138 Centre de Recherche des Cordeliers Paris France
INSERM U1259 MAVIVH Université de Tours Tours France
INSERM UMRS_1166 iCAN Institute of Cardiometabolism and Nutrition Paris France
Institut d'Investigacions Biomèdiques August Pi i Sunyer Barcelona Spain
Institut Hospitalo Universitaire Méditerranée Infection Marseille France
Institut Pasteur de Lille Lille France
Institute for Biomedical Research Spanish Research Council Barcelona Spain
Institute for Systems Biology Seattle WA 98109 USA
Institute of Biomedicine and Translational Medicine University of Tartu Tartu Estonia
Institute of public health of Republic of North Macedonia
Intensive Care Department Donostia University Hospital San Sebastian Spain
Intensive Care Unit Grand Hôpital de l'Est Francilien Site de Marne la Vallée Jossigny France
Internal Medicine Department Lariboisière Hospital AP HP Paris University Paris France
Laboratoire d'Immunologie Hospices Civils de Lyon Hôpital Edouard Herriot Lyon France
Laboratory of Human Genetics and Genomics The Rockefeller University New York NY
Laboratory of Molecular Immunology Rockefeller University New York NY USA
Laboratory of Virology and Infectious Disease The Rockefeller University New York NY USA
Medical Intensive care Unit University Hospitals Leuven Leuven Belgium
Meram Medical Faculty Necmettin Erbakan University Meram Medical Faculty Konya Turkey
NIAID Clinical Genomics Program National Institutes of Health Bethesda USA
Paris Cardiovascular Center PARCC Inserm Université de Paris Paris France
Pathogenesis and Therapy of Primary Immunodeficiencies Unit San Raffaele Milano Italy
Precision Medicine Unit Lausanne University Hospital and University of Lausanne Lausanne Switzerland
Primary Immunodeficiencies Group University of Antioquia UdeA Medellin Colombia
Réanimation Médicale et Toxicologique Hôpital Lariboisière 1144
Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel
SAINBIOSE INSERM U1059 University of Lyon Université Jean Monnet Saint Etienne
School of Life Sciences Ecole Polytechnique Fédérale de Lausanne Lausanne Switzerland
School of Microbiology University of Antioquia UdeA Medellin Colombia
Service de Bactériologie Virologie Hygiène CHU de Tours Tours France
Service de Biologie Clinique and UMR S 1176 Hopital Foch Suresnes France
Service de Biologie Médicale CHI Robert Ballanger Aulnay sous Bois France
Service de Médecine Interne Hôpital universitaire Jean Verdier AP HP Bondy France
Service de Parasitologie Mycologie Groupe Hospitalier Pitié Salpêtrière AP HP Paris France
Shupyk National Healthcare University of Ukraine Kyiv Ukraine
Sorbonne Université Inserm Centre d'Immunologie et des Maladies Infectieuses Paris France
Swiss Institue of Bioinformatics Lausanne Switzerland
The Genetics Institute Tel Aviv Sourasky Medical Center Tel Aviv University Tel Aviv Israel
Translational Immunology Lab Institut Pasteur
UMR 1098 RIGHT Inserm EFS Université de Franche Comté Besançon France
Université de Lille Inserm CHU Lille Institut Pasteur de Lille U1011 EGID F 59000 Lille France
Université de Paris IAME UMR S 1137 INSERM Paris France
Université de Paris Université Paris Saclay UVSQ Inserm UMS11 Villejuif France
University of Bordeaux INSERM Bordeaux Population Health Center UMR1219 F 33000 Bordeaux France
University of Lille U1019 UMR9017 Center for Infection and Immunity of Lille Lille France
University of Paris Imagine Institute Paris France
University of Sao Paulo Sao Paulo Brazil
Yale Center for Genome Analysis Yale School of Medicine New Haven CT USA
Zobrazit více v PubMed
Levin A. T., Hanage W. P., Owusu-Boaitey N., Cochran K. B., Walsh S. P., Meyerowitz-Katz G., Assessing the age specificity of infection fatality rates for COVID-19: Systematic review, meta-analysis, and public policy implications. Eur. J. Epidemiol. 35, 1123–1138 (2020). 10.1007/s10654-020-00698-1 PubMed DOI PMC
O’Driscoll M., Ribeiro Dos Santos G., Wang L., Cummings D. A. T., Azman A. S., Paireau J., Fontanet A., Cauchemez S., Salje H., Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 590, 140–145 (2021). 10.1038/s41586-020-2918-0 PubMed DOI
Williamson E. J., Walker A. J., Bhaskaran K., Bacon S., Bates C., Morton C. E., Curtis H. J., Mehrkar A., Evans D., Inglesby P., Cockburn J., McDonald H. I., MacKenna B., Tomlinson L., Douglas I. J., Rentsch C. T., Mathur R., Wong A. Y. S., Grieve R., Harrison D., Forbes H., Schultze A., Croker R., Parry J., Hester F., Harper S., Perera R., Evans S. J. W., Smeeth L., Goldacre B., Factors associated with COVID-19-related death using OpenSAFELY. Nature 584, 430–436 (2020). 10.1038/s41586-020-2521-4 PubMed DOI PMC
Brodin P., Immune determinants of COVID-19 disease presentation and severity. Nat. Med. 27, 28–33 (2021). 10.1038/s41591-020-01202-8 PubMed DOI
Zhang Q., Bastard P., Bolze A., Jouanguy E., Zhang S. Y., Cobat A., Notarangelo L. D., Su H. C., Abel L., Casanova J. L.; COVID Human Genetic Effort , Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation. Med (N Y) 1, 14–20 (2020). PubMed PMC
Casanova J. L., Su H. C.; COVID Human Genetic Effort , A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection. Cell 181, 1194–1199 (2020). 10.1016/j.cell.2020.05.016 PubMed DOI PMC
Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., Ogishi M., Sabli I. K. D., Hodeib S., Korol C., Rosain J., Bilguvar K., Ye J., Bolze A., Bigio B., Yang R., Arias A. A., Zhou Q., Zhang Y., Onodi F., Korniotis S., Karpf L., Philippot Q., Chbihi M., Bonnet-Madin L., Dorgham K., Smith N., Schneider W. M., Razooky B. S., Hoffmann H.-H., Michailidis E., Moens L., Han J. E., Lorenzo L., Bizien L., Meade P., Neehus A.-L., Ugurbil A. C., Corneau A., Kerner G., Zhang P., Rapaport F., Seeleuthner Y., Manry J., Masson C., Schmitt Y., Schlüter A., Le Voyer T., Khan T., Li J., Fellay J., Roussel L., Shahrooei M., Alosaimi M. F., Mansouri D., Al-Saud H., Al-Mulla F., Almourfi F., Al-Muhsen S. Z., Alsohime F., Al Turki S., Hasanato R., van de Beek D., Biondi A., Bettini L. R., D’Angio’ M., Bonfanti P., Imberti L., Sottini A., Paghera S., Quiros-Roldan E., Rossi C., Oler A. J., Tompkins M. F., Alba C., Vandernoot I., Goffard J.-C., Smits G., Migeotte I., Haerynck F., Soler-Palacin P., Martin-Nalda A., Colobran R., Morange P.-E., Keles S., Çölkesen F., Ozcelik T., Yasar K. K., Senoglu S., Karabela Ş. N., Rodríguez-Gallego C., Novelli G., Hraiech S., Tandjaoui-Lambiotte Y., Duval X., Laouénan C., Snow A. L., Dalgard C. L., Milner J. D., Vinh D. C., Mogensen T. H., Marr N., Spaan A. N., Boisson B., Boisson-Dupuis S., Bustamante J., Puel A., Ciancanelli M. J., Meyts I., Maniatis T., Soumelis V., Amara A., Nussenzweig M., García-Sastre A., Krammer F., Pujol A., Duffy D., Lifton R. P., Zhang S.-Y., Gorochov G., Béziat V., Jouanguy E., Sancho-Shimizu V., Rice C. M., Abel L., Notarangelo L. D., Cobat A., Su H. C., Casanova J.-L.; COVID-STORM Clinicians; COVID Clinicians; Imagine COVID Group; French COVID Cohort Study Group; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort; NIAID-USUHS/TAGC COVID Immunity Group , Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020). 10.1126/science.abd4570 PubMed DOI PMC
Novelli G., Biancolella M., Mehrian-Shai R., Colona V. L., Brito A. F., Grubaugh N. D., Vasiliou V., Luzzatto L., Reichardt J. K. V., COVID-19 one year into the pandemic: From genetics and genomics to therapy, vaccination, and policy. Hum. Genomics 15, 27 (2021). 10.1186/s40246-021-00326-3 PubMed DOI PMC
Bastard P., Rosen L. B., Zhang Q., Michailidis E., Hoffmann H.-H., Zhang Y., Dorgham K., Philippot Q., Rosain J., Béziat V., Manry J., Shaw E., Haljasmägi L., Peterson P., Lorenzo L., Bizien L., Trouillet-Assant S., Dobbs K., de Jesus A. A., Belot A., Kallaste A., Catherinot E., Tandjaoui-Lambiotte Y., Le Pen J., Kerner G., Bigio B., Seeleuthner Y., Yang R., Bolze A., Spaan A. N., Delmonte O. M., Abers M. S., Aiuti A., Casari G., Lampasona V., Piemonti L., Ciceri F., Bilguvar K., Lifton R. P., Vasse M., Smadja D. M., Migaud M., Hadjadj J., Terrier B., Duffy D., Quintana-Murci L., van de Beek D., Roussel L., Vinh D. C., Tangye S. G., Haerynck F., Dalmau D., Martinez-Picado J., Brodin P., Nussenzweig M. C., Boisson-Dupuis S., Rodríguez-Gallego C., Vogt G., Mogensen T. H., Oler A. J., Gu J., Burbelo P. D., Cohen J. I., Biondi A., Bettini L. R., D’Angio M., Bonfanti P., Rossignol P., Mayaux J., Rieux-Laucat F., Husebye E. S., Fusco F., Ursini M. V., Imberti L., Sottini A., Paghera S., Quiros-Roldan E., Rossi C., Castagnoli R., Montagna D., Licari A., Marseglia G. L., Duval X., Ghosn J., Tsang J. S., Goldbach-Mansky R., Kisand K., Lionakis M. S., Puel A., Zhang S.-Y., Holland S. M., Gorochov G., Jouanguy E., Rice C. M., Cobat A., Notarangelo L. D., Abel L., Su H. C., Casanova J.-L.; HGID Lab; NIAID-USUHS Immune Response to COVID Group; COVID Clinicians; COVID-STORM Clinicians; Imagine COVID Group; French COVID Cohort Study Group; Milieu Intérieur Consortium; CoV-Contact Cohort; Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort , Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585 (2020). 10.1126/science.abd4585 PubMed DOI PMC
Lazear H. M., Schoggins J. W., Diamond M. S., Shared and Distinct Functions of Type I and Type III Interferons. Immunity 50, 907–923 (2019). 10.1016/j.immuni.2019.03.025 PubMed DOI PMC
Koning R., Bastard P., Casanova J.-L., Brouwer M. C., van de Beek D.; with the Amsterdam U.M.C. COVID-19 Biobank Investigators , Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients. Intensive Care Med. 47, 704–706 (2021). 10.1007/s00134-021-06392-4 PubMed DOI PMC
Troya J., Bastard P., Planas-Serra L., Ryan P., Ruiz M., de Carranza M., Torres J., Martínez A., Abel L., Casanova J.-L., Pujol A., Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain. J. Clin. Immunol. 41, 914–922 (2021). 10.1007/s10875-021-01036-0 PubMed DOI PMC
Vazquez S. E., Bastard P., Kelly K., Gervais A., Norris P. J., Dumont L. J., Casanova J.-L., Anderson M. S., DeRisi J. L., Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma. J. Clin. Immunol. 41, 1169–1171 (2021). 10.1007/s10875-021-01060-0 PubMed DOI PMC
Goncalves D., et al. ., Antibodies against type-I Interferon: detection and association with severe clinical outcome in COVID-19 patients. medRxiv, (2021). PubMed PMC
Wang E. Y., Mao T., Klein J., Dai Y., Huck J. D., Jaycox J. R., Liu F., Zhou T., Israelow B., Wong P., Coppi A., Lucas C., Silva J., Oh J. E., Song E., Perotti E. S., Zheng N. S., Fischer S., Campbell M., Fournier J. B., Wyllie A. L., Vogels C. B. F., Ott I. M., Kalinich C. C., Petrone M. E., Watkins A. E., Dela Cruz C., Farhadian S. F., Schulz W. L., Ma S., Grubaugh N. D., Ko A. I., Iwasaki A., Ring A. M.; Yale IMPACT Team , Diverse functional autoantibodies in patients with COVID-19. Nature 595, 283–288 (2021). 10.1038/s41586-021-03631-y PubMed DOI
van der Wijst M. G. P., et al. ., Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19. bioRxiv, (2021).
Levin M., Anti-interferon auto-antibodies in autoimmune polyendocrinopathy syndrome type 1. PLOS Med. 3, e292 (2006). 10.1371/journal.pmed.0030292 PubMed DOI PMC
Meager A., Visvalingam K., Peterson P., Möll K., Murumägi A., Krohn K., Eskelin P., Perheentupa J., Husebye E., Kadota Y., Willcox N., Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLOS Med. 3, e289 (2006). 10.1371/journal.pmed.0030289 PubMed DOI PMC
Meyer S., Woodward M., Hertel C., Vlaicu P., Haque Y., Kärner J., Macagno A., Onuoha S. C., Fishman D., Peterson H., Metsküla K., Uibo R., Jäntti K., Hokynar K., Wolff A. S. B., Krohn K., Ranki A., Peterson P., Kisand K., Hayday A.; APECED patient collaborative , AIRE-Deficient Patients Harbor Unique High-Affinity Disease-Ameliorating Autoantibodies. Cell 166, 582–595 (2016). 10.1016/j.cell.2016.06.024 PubMed DOI PMC
Bastard P., Orlova E., Sozaeva L., Lévy R., James A., Schmitt M. M., Ochoa S., Kareva M., Rodina Y., Gervais A., Le Voyer T., Rosain J., Philippot Q., Neehus A.-L., Shaw E., Migaud M., Bizien L., Ekwall O., Berg S., Beccuti G., Ghizzoni L., Thiriez G., Pavot A., Goujard C., Frémond M.-L., Carter E., Rothenbuhler A., Linglart A., Mignot B., Comte A., Cheikh N., Hermine O., Breivik L., Husebye E. S., Humbert S., Rohrlich P., Coaquette A., Vuoto F., Faure K., Mahlaoui N., Kotnik P., Battelino T., Trebušak Podkrajšek K., Kisand K., Ferré E. M. N., DiMaggio T., Rosen L. B., Burbelo P. D., McIntyre M., Kann N. Y., Shcherbina A., Pavlova M., Kolodkina A., Holland S. M., Zhang S.-Y., Crow Y. J., Notarangelo L. D., Su H. C., Abel L., Anderson M. S., Jouanguy E., Neven B., Puel A., Casanova J.-L., Lionakis M. S., Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J. Exp. Med. 218, e20210554 (2021). 10.1084/jem.20210554 PubMed DOI PMC
Meisel C., Akbil B., Meyer T., Lankes E., Corman V. M., Staudacher O., Unterwalder N., Kölsch U., Drosten C., Mall M. A., Kallinich T., Schnabel D., Goffinet C., von Bernuth H., Mild COVID-19 despite autoantibodies against type I IFNs in autoimmune polyendocrine syndrome type 1. J. Clin. Invest. 131, e150867 (2021). 10.1172/JCI150867 PubMed DOI PMC
Walter J. E., Rosen L. B., Csomos K., Rosenberg J. M., Mathew D., Keszei M., Ujhazi B., Chen K., Lee Y. N., Tirosh I., Dobbs K., Al-Herz W., Cowan M. J., Puck J., Bleesing J. J., Grimley M. S., Malech H., De Ravin S. S., Gennery A. R., Abraham R. S., Joshi A. Y., Boyce T. G., Butte M. J., Nadeau K. C., Balboni I., Sullivan K. E., Akhter J., Adeli M., El-Feky R. A., El-Ghoneimy D. H., Dbaibo G., Wakim R., Azzari C., Palma P., Cancrini C., Capuder K., Condino-Neto A., Costa-Carvalho B. T., Oliveira J. B., Roifman C., Buchbinder D., Kumanovics A., Franco J. L., Niehues T., Schuetz C., Kuijpers T., Yee C., Chou J., Masaad M. J., Geha R., Uzel G., Gelman R., Holland S. M., Recher M., Utz P. J., Browne S. K., Notarangelo L. D., Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J. Clin. Invest. 125, 4135–4148 (2015). 10.1172/JCI80477 PubMed DOI PMC
Rosenberg J. M., Maccari M. E., Barzaghi F., Allenspach E. J., Pignata C., Weber G., Torgerson T. R., Utz P. J., Bacchetta R., Neutralizing Anti-Cytokine Autoantibodies Against Interferon-α in Immunodysregulation Polyendocrinopathy Enteropathy X-Linked. Front. Immunol. 9, 544 (2018). 10.3389/fimmu.2018.00544 PubMed DOI PMC
Vallbracht A., Treuner J., Flehmig B., Joester K. E., Niethammer D., Interferon-neutralizing antibodies in a patient treated with human fibroblast interferon. Nature 289, 496–497 (1981). 10.1038/289496a0 PubMed DOI
Rudick R. A., Simonian N. A., Alam J. A., Campion M., Scaramucci J. O., Jones W., Coats M. E., Goodkin D. E., Weinstock-Guttman B., Herndon R. M., Mass M. K., Richert J. R., Salazar A. M., Munschauer F. E. 3rd, Cookfair D. L., Simon J. H., Jacobs L. D.; Multiple Sclerosis Collaborative Research Group (MSCRG) , Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Neurology 50, 1266–1272 (1998). 10.1212/WNL.50.5.1266 PubMed DOI
Panem S., Check I. J., Henriksen D., Vilcek J., Antibodies to alpha-interferon in a patient with systemic lupus erythematosus. J. Immunol. 129, 1–3 (1982). PubMed
Gupta S., Tatouli I. P., Rosen L. B., Hasni S., Alevizos I., Manna Z. G., Rivera J., Jiang C., Siegel R. M., Holland S. M., Moutsopoulos H. M., Browne S. K., Distinct Functions of Autoantibodies Against Interferon in Systemic Lupus Erythematosus: A Comprehensive Analysis of Anticytokine Autoantibodies in Common Rheumatic Diseases. Arthritis Rheumatol. 68, 1677–1687 (2016). 10.1002/art.39607 PubMed DOI PMC
Shiono H., Wong Y. L., Matthews I., Liu J. L., Zhang W., Sims G., Meager A., Beeson D., Vincent A., Willcox N., Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int. Immunol. 15, 903–913 (2003). 10.1093/intimm/dxg088 PubMed DOI
Bello-Rivero I., Cervantes M., Torres Y., Ferrero J., Rodríguez E., Pérez J., García I., Díaz G., López-Saura P., Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping. J. Autoimmun. 23, 63–73 (2004). 10.1016/j.jaut.2004.03.013 PubMed DOI
Meager A., Wadhwa M., Dilger P., Bird C., Thorpe R., Newsom-Davis J., Willcox N., Anti-cytokine autoantibodies in autoimmunity: Preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin. Exp. Immunol. 132, 128–136 (2003). 10.1046/j.1365-2249.2003.02113.x PubMed DOI PMC
Bastard P., Michailidis E., Hoffmann H.-H., Chbihi M., Le Voyer T., Rosain J., Philippot Q., Seeleuthner Y., Gervais A., Materna M., de Oliveira P. M. N., Maia M. L. S., Dinis Ano Bom A. P., Azamor T., Araújo da Conceição D., Goudouris E., Homma A., Slesak G., Schäfer J., Pulendran B., Miller J. D., Huits R., Yang R., Rosen L. B., Bizien L., Lorenzo L., Chrabieh M., Erazo L. V., Rozenberg F., Jeljeli M. M., Béziat V., Holland S. M., Cobat A., Notarangelo L. D., Su H. C., Ahmed R., Puel A., Zhang S.-Y., Abel L., Seligman S. J., Zhang Q., MacDonald M. R., Jouanguy E., Rice C. M., Casanova J.-L., Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J. Exp. Med. 218, e20202486 (2021). 10.1084/jem.20202486 PubMed DOI PMC
Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N., Péré H., Charbit B., Bondet V., Chenevier-Gobeaux C., Breillat P., Carlier N., Gauzit R., Morbieu C., Pène F., Marin N., Roche N., Szwebel T.-A., Merkling S. H., Treluyer J.-M., Veyer D., Mouthon L., Blanc C., Tharaux P.-L., Rozenberg F., Fischer A., Duffy D., Rieux-Laucat F., Kernéis S., Terrier B., Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718–724 (2020). 10.1126/science.abc6027 PubMed DOI PMC
Trouillet-Assant S., Viel S., Gaymard A., Pons S., Richard J.-C., Perret M., Villard M., Brengel-Pesce K., Lina B., Mezidi M., Bitker L., Belot A.; COVID HCL Study group , Type I IFN immunoprofiling in COVID-19 patients. J. Allergy Clin. Immunol. 146, 206–208.e2 (2020). 10.1016/j.jaci.2020.04.029 PubMed DOI PMC
Honda N., Lindberg U., Andersson P., Hoffmann S., Takei H., Simultaneous multiple immunoassays in a compact disc-shaped microfluidic device based on centrifugal force. Clin. Chem. 51, 1955–1961 (2005). 10.1373/clinchem.2005.053348 PubMed DOI
M. G. P. v. d. Wijst et al., Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19. Submitted (2021).
Asano T., et al. ., X-linked recessive TLR7 deficiency in 1% of men under 60 years with life-threatening COVID-19. Sci. Immunol. 6, eabl4348 (2021). PubMed PMC
Bastard P., Lévy R., Henriquez S., Bodemer C., Szwebel T.-A., Casanova J.-L., Interferon-β Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2. J. Clin. Immunol. 41, 931–933 (2021). 10.1007/s10875-021-01023-5 PubMed DOI PMC
Monk P. D., Marsden R. J., Tear V. J., Brookes J., Batten T. N., Mankowski M., Gabbay F. J., Davies D. E., Holgate S. T., Ho L.-P., Clark T., Djukanovic R., Wilkinson T. M. A.; Inhaled Interferon Beta COVID-19 Study Group , Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 9, 196–206 (2021). 10.1016/S2213-2600(20)30511-7 PubMed DOI PMC
Hooper B., Whittingham S., Mathews J. D., Mackay I. R., Curnow D. H., Autoimmunity in a rural community. Clin. Exp. Immunol. 12, 79–87 (1972). PubMed PMC
Shu S., Nisengard R. J., Hale W. L., Beutner E. H., Incidence and titers of antinuclear, antismooth muscle, and other autoantibodies in blood donors. J. Lab. Clin. Med. 86, 259–265 (1975). PubMed
Potocka-Płazak K., Pituch-Noworolska A., Kocemba J., [Prevalence of autoantibodies in serum of healthy persons over 85 years of age]. Przegl. Lek. 52, 544–546 (1995) [Prevalence of autoantibodies in serum of healthy persons over 85 years of age]. PubMed
Parks C. G., Miller F. W., Satoh M., Chan E. K. L., Andrushchenko Z., Birnbaum L. S., Jusko T. A., Kissling G. E., Patel M. D., Rose K. M., Weinberg C., Zeldin D. C., Sandler D. P., Reproductive and hormonal risk factors for antinuclear antibodies (ANA) in a representative sample of U.S. women. Cancer Epidemiol. Biomarkers Prev. 23, 2492–2502 (2014). 10.1158/1055-9965.EPI-14-0429 PubMed DOI PMC
Myasoedova E., Davis J., Matteson E. L., Crowson C. S., Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985-2014. Ann. Rheum. Dis. 79, 440–444 (2020). 10.1136/annrheumdis-2019-216694 PubMed DOI PMC
Sanchez-Felipe L., Vercruysse T., Sharma S., Ma J., Lemmens V., Van Looveren D., Arkalagud Javarappa M. P., Boudewijns R., Malengier-Devlies B., Liesenborghs L., Kaptein S. J. F., De Keyzer C., Bervoets L., Debaveye S., Rasulova M., Seldeslachts L., Li L.-H., Jansen S., Yakass M. B., Verstrepen B. E., Böszörményi K. P., Kiemenyi-Kayere G., van Driel N., Quaye O., Zhang X., Ter Horst S., Mishra N., Deboutte W., Matthijnssens J., Coelmont L., Vandermeulen C., Heylen E., Vergote V., Schols D., Wang Z., Bogers W., Kuiken T., Verschoor E., Cawthorne C., Van Laere K., Opdenakker G., Vande Velde G., Weynand B., Teuwen D. E., Matthys P., Neyts J., Jan Thibaut H., Dallmeier K., A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature 590, 320–325 (2021). 10.1038/s41586-020-3035-9 PubMed DOI
Chen P., Nirula A., Heller B., Gottlieb R. L., Boscia J., Morris J., Huhn G., Cardona J., Mocherla B., Stosor V., Shawa I., Adams A. C., Van Naarden J., Custer K. L., Shen L., Durante M., Oakley G., Schade A. E., Sabo J., Patel D. R., Klekotka P., Skovronsky D. M.; BLAZE-1 Investigators , SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N. Engl. J. Med. 384, 229–237 (2021). 10.1056/NEJMoa2029849 PubMed DOI PMC
Weinreich D. M., Sivapalasingam S., Norton T., Ali S., Gao H., Bhore R., Musser B. J., Soo Y., Rofail D., Im J., Perry C., Pan C., Hosain R., Mahmood A., Davis J. D., Turner K. C., Hooper A. T., Hamilton J. D., Baum A., Kyratsous C. A., Kim Y., Cook A., Kampman W., Kohli A., Sachdeva Y., Graber X., Kowal B., DiCioccio T., Stahl N., Lipsich L., Braunstein N., Herman G., Yancopoulos G. D.; Trial Investigators , REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N. Engl. J. Med. 384, 238–251 (2021). 10.1056/NEJMoa2035002 PubMed DOI PMC
de Prost N., Bastard P., Arrestier R., Fourati S., Mahévas M., Burrel S., Dorgham K., Gorochov G., Tandjaoui-Lambiotte Y., Azzaoui I., Fernandes I., Combes A., Casanova J.-L., Mekontso-Dessap A., Luyt C.-E., Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia. J. Clin. Immunol. 41, 536–544 (2021). 10.1007/s10875-021-00994-9 PubMed DOI PMC
Vinh D. C., Abel L., Bastard P., Cheng M. P., Condino-Neto A., Gregersen P. K., Haerynck F., Cicalese M. P., Hagin D., Soler-Palacín P., Planas A. M., Pujol A., Notarangelo L. D., Zhang Q., Su H. C., Casanova J. L., Meyts I.; COVID Human Genetic Effort , Harnessing type I IFN immunity against SARS-CoV-2 with early administration of IFN-beta. JoCI, in press (2021). PubMed PMC
Firth D., Bias reduction of maximum likelihood estimates. Biometrika 80, 27–38 (1993). 10.1093/biomet/80.1.27 DOI
Heinze G., Schemper M., A solution to the problem of separation in logistic regression. Stat. Med. 21, 2409–2419 (2002). 10.1002/sim.1047 PubMed DOI
Agresti A., Coull B. A., Approximate is better than “exact” for interval estimation of binomial proportions. Am. Stat. 52, 119–126 (1998).
Autoantibodies neutralizing type I IFNs underlie severe tick-borne encephalitis in ∼10% of patients
Autoantibodies against type I IFNs in humans with alternative NF-κB pathway deficiency
Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies